Search

Your search keyword '"Pehlivan, Tamer"' showing total 11 results
Start Over Author "Pehlivan, Tamer"
11 results on '"Pehlivan, Tamer"'

3. Influenza vaccination situation in Middle-East and North Africa countries: Report of the 7th MENA Influenza Stakeholders Network (MENA-ISN)

Author

Al Awaidi, Salah, Abusrewil, Suleiman, AbuHasan, Muslim, Akcay, Meral, Aksakal, Fatma N.B., Bashir, Uzma, Elahmer, Omar, Esteghamati, Abdoulreza, Gahwagi, Milad, Mirza, Yusuf K., Grasso, Cindy, Kassianos, George, Khris, Moulud, Mardani, Masoud, Maltezou, Helena, Nourlil, Jalal, Oumzil, Hicham, Osterhaus, Ab, Picot, Valentina, Pehlivan, Tamer, Saadatian-Elahi, Mitra, Tali, İlham, Tarraf, Hesham, Ugur, Baris, and Zaraket, Hassan

Published
2018
Full Text
View/download PDF

6. Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life

Author

Kanra, Güler, Silier, Thomas, Yurdakök, Kadriye, Yavuz, Tuna, Baskan, Sevgi, Ulukol, Betül, Ceyhan, Mehmet, Özmert, Elif, Türkay, Fikri, and Pehlivan, Tamer

Published
1999
Full Text
View/download PDF

9. Measles seroprevalence in Izmir with special emphasis on measles vaccination policy for Turkey.

Author

Aksit, Sadik, Egemen, Ayten, Ozacar, Tijen, Kurugol, Zafer, Keskinoglu, Pembe, Pehlivan, Tamer, and Mutlu, Sefika

Subjects
MEASLES, MEASLES vaccines, IMMUNOGLOBULINS
Abstract

Abstract Background: Measles outbreaks seem to occur every 2- to 3-year intervals in Turkey. However, sero-epidemiological studies are limited. Knowing the prevalence of measles susceptibility as measured either by serologic markers of immunity or surveys of vaccination coverage is an important tool to assess the risk for measles outbreaks. Methods: In order to determine the seroprevalence of measles antibodies among a 1 to 29-year-old population in İzmir (Turkey) and to develop the best vaccination policy for measles, a total of 600 people aged from 1 to 29 were selected for the study with cluster sampling. The information on sociodemographic characteristics, vaccination status and measles history was gathered for each participant. Measles-specific IgG antibodies were screened qualitatively by using microenzyme immune assay for 595 subjects. Results: Of the 595 participants screened for the measles antibodies, 56 (9.4%) were seronegative. The proportion of the susceptible individuals in the age groups of 1–4, 5–9, 10–14, 15–19 and 20–29 was 20.0, 10.4, 6.0, 10.3 and 3.0%, respectively. The logistic regression analysis showed that none of the independent characteristics (sex, socioeconomic status, past measles history, vaccination status) with the exception of age group, was significantly associated with measles seronegativity. Conclusion: The optimal measles vaccination policy for Turkey may be to increase vaccination coverage above 90%, to conduct a catch-up campaign covering persons aged 1–19, regardless of previous vaccination status. Another factor to consider is to adopt a routine two-dose vaccination, giving the first dose at 12_15 months of age and the second dose at school entry. [ABSTRACT FROM AUTHOR]

Published
2001

11. Immunogenicity and safety of Haemophilus influenzaetype b capsular polysaccharide tetanus conjugate vaccine (PRP‐T) presented in a dual‐chamber syringe with DTP

Author

KANRA, GÜLER, YURDAKÖK, KADRIYE, CEYHAN, MEHMET, ÖZMERT, ELIF, TÜRKAY, FIKRI, and PEHLIVAN, TAMER

Abstract

Separate injections of Haemophilus influenzaetype b capsular polysaccharide‐tetanus conjugate (PRP‐T) vaccine and diphtheria‐tetanus‐pertussis (DTP) reconstitution of freeze‐dried PRP‐T vaccine with liquid DTP vaccine have been shown to be safe and immunogenic in infants. The present study was conducted to test the safety and immunogenicity of the liquid combination vaccine administered to young infants in the dual‐chamber syringe. The study was a monocenter, open clinical trial of 3 month‐old infants receiving PRP‐T and DTP vaccines in the dual‐chamber syringe reconstituted prior to injection. Healthy infants were immunized according to a 3, 4 and 5 months‐of‐age schedule. The vaccine was administered in a dual‐chamber syringe, ready to use with two chambers. The proximal chamber contained freeze‐dried PRP‐T and the distal chamber contained liquid combination‐vaccine DTP. The freeze‐dried PRP‐T vaccine was reconstituted with the liquid DTP vaccine in the same unidose dual‐chamber syringe (0.5 mL) and was injected intramuscularly into the deltoid region. Blood sampling was performed prior to vaccination at 3 months of age and after the third vaccination at 6 months. The primary end‐point was the serological response to PRP‐T vaccine as expressed by the percentage of infants with an antibody titer greater than or equal to 1 μg/mL. The reactogenicity was expressed as the percentage of reported local and systemic reactions. A total of 108 infants were included in the study and received the dual‐chamber syringe vaccine. After the third injection, all the infants had a PRP antibody titer greater than or equal to 0.15 μg/mL and 94.4% of infants had a PRP antibody titer greater than or equal to 1 μg/mL; the pertussis agglutinin titers were over the threshold 40 and 80 in all infants and 98.1% were over the threshold 320. After the third injection, all the infants had diphtheria antibody titers greater than 0.1 IU/mL and 83.3% had titers greater than 1 IU/mL; all the infants had tetanus antibody titers greater than 0.1 IU/mL and 97.2% had results over 1 IU/mL. Thirty‐seven infants (34.6%) had local reactions and 64.5% had systemic reactions. The dual‐chamber syringe may reduce the cost of vaccine delivery, as well as the workload, and increase the vaccine acceptability and coverage rate of vaccines.

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results